

John W. Eikelboom

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9156826/publications.pdf>

Version: 2024-02-01

717
papers

80,612
citations

906

116
h-index

471

271
g-index

738
all docs

738
docs citations

738
times ranked

45092
citing authors

#	ARTICLE	IF	CITATIONS
1	Dabigatran versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2009, 361, 1139-1151.	27.0	9,839
2	Edoxaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2013, 369, 2093-2104.	27.0	4,215
3	Standardized Bleeding Definitions for Cardiovascular Clinical Trials. <i>Circulation</i> , 2011, 123, 2736-2747.	1.6	3,378
4	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2950-2973.	2.8	2,392
5	Apixaban in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 364, 806-817.	27.0	2,207
6	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1319-1330.	27.0	1,745
7	Idarucizumab for Dabigatran Reversal. <i>New England Journal of Medicine</i> , 2015, 373, 511-520.	27.0	1,419
8	Dabigatran versus Warfarin in Patients with Mechanical Heart Valves. <i>New England Journal of Medicine</i> , 2013, 369, 1206-1214.	27.0	1,201
9	Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes. <i>Circulation</i> , 2006, 114, 774-782.	1.6	1,196
10	Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events. <i>Circulation</i> , 2002, 105, 1650-1655.	1.6	1,040
11	Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation. <i>Circulation</i> , 2011, 123, 2363-2372.	1.6	1,035
12	Colchicine in Patients with Chronic Coronary Disease. <i>New England Journal of Medicine</i> , 2020, 383, 1838-1847.	27.0	1,010
13	Homocysteine and vascular disease. <i>Lancet, The</i> , 1999, 354, 407-413.	13.7	914
14	Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. <i>Lancet, The</i> , 2010, 376, 975-983.	13.7	913
15	Idarucizumab for Dabigatran Reversal – Full Cohort Analysis. <i>New England Journal of Medicine</i> , 2017, 377, 431-441.	27.0	858
16	Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 148-156.	3.8	813
17	Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range. <i>Circulation</i> , 2008, 118, 2029-2037.	1.6	789
18	Homocyst(e)ine and Cardiovascular Disease: A Critical Review of the Epidemiologic Evidence. <i>Annals of Internal Medicine</i> , 1999, 131, 363.	3.9	781

#	ARTICLE	IF	CITATIONS
19	Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease. Journal of the American College of Cardiology, 2013, 61, 404-410.	2.8	749
20	Myocardial Injury after Noncardiac Surgery. Anesthesiology, 2014, 120, 564-578.	2.5	740
21	Aspirin in Patients Undergoing Noncardiac Surgery. New England Journal of Medicine, 2014, 370, 1494-1503.	27.0	735
22	The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients. Journal of the American College of Cardiology, 2014, 63, 321-328.	2.8	733
23	Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet, The, 2010, 376, 1233-1243.	13.7	725
24	Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. New England Journal of Medicine, 2016, 375, 1131-1141.	27.0	692
25	Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. New England Journal of Medicine, 2019, 380, 1326-1335.	27.0	687
26	Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes. New England Journal of Medicine, 2010, 363, 930-942.	27.0	681
27	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet, The, 2018, 391, 219-229.	13.7	651
28	Thrombolysis Compared With Heparin for the Initial Treatment of Pulmonary Embolism. Circulation, 2004, 110, 744-749.	1.6	578
29	Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. New England Journal of Medicine, 2019, 380, 720-728.	27.0	520
30	Aspirin resistance. Lancet, The, 2006, 367, 606-617.	13.7	503
31	Effects of <i>CYP2C19</i> Genotype on Outcomes of Clopidogrel Treatment. New England Journal of Medicine, 2010, 363, 1704-1714.	27.0	497
32	Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin. Circulation, 2012, 126, 343-348.	1.6	494
33	Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet, The, 2001, 358, 9-15.	13.7	489
34	Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism. New England Journal of Medicine, 2012, 367, 1979-1987.	27.0	453
35	Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial. Circulation, 2013, 127, 634-640.	1.6	447
36	Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation, 2019, 140, 240-261.	1.6	428

#	ARTICLE	IF	CITATIONS
37	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018, 391, 205-218.	13.7	426
38	Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. <i>Lancet, The</i> , 2000, 355, 1936-1942.	13.7	419
39	Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies. <i>Circulation</i> , 2010, 121, 1188-1199.	1.6	419
40	Management of Antiphospholipid Antibody Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1050.	7.4	390
41	The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. <i>Lancet, The</i> , 2016, 387, 2302-2311.	13.7	389
42	Oral Anticoagulant and Antiplatelet Therapy and Peripheral Arterial Disease. <i>New England Journal of Medicine</i> , 2007, 357, 217-227.	27.0	383
43	Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal Insufficiency. <i>Annals of Internal Medicine</i> , 2006, 144, 673.	3.9	365
44	Impact of right ventricular involvement on mortality and morbidity in patients with inferior myocardial infarction. Drs. Mehta and Eikelboom were recipients of Heart and Stroke Foundation of Canada Research Fellowship Awards. Professor Yusuf is the recipient of a Medical Research Council of Canada Senior Scientist Award and holds a Heart and Stroke Foundation of Ontario Research Chair. <i>Journal of the American College of Cardiology</i> , 2001, 37, 37-43.	2.8	364
45	Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial. <i>Circulation</i> , 2012, 125, 669-676.	1.6	348
46	Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation. <i>Circulation</i> , 2014, 129, 961-970.	1.6	346
47	Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. <i>European Heart Journal</i> , 2011, 32, 1854-1864.	2.2	343
48	A Test in Context: D-Dimer. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2411-2420.	2.8	342
49	Dabigatran Etexilate. <i>Circulation</i> , 2011, 123, 1436-1450.	1.6	340
50	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. <i>European Heart Journal</i> , 2019, 40, 2632-2653.	2.2	335
51	Low-Molecular-Weight Heparin Compared with Intravenous Unfractionated Heparin for Treatment of Pulmonary Embolism. <i>Annals of Internal Medicine</i> , 2004, 140, 175.	3.9	333
52	Antiplatelet Drugs. <i>Chest</i> , 2012, 141, e89S-e119S.	0.8	318
53	Aspirin resistance: position paper of the Working Group on Aspirin Resistance. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1309-1311.	3.8	315
54	Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: A systematic review of randomized trials. <i>Thrombosis Research</i> , 2009, 123, 687-696.	1.7	300

#	ARTICLE	IF	CITATIONS
55	Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. <i>Gastroenterology</i> , 2019, 157, 682-691.e2.	1.3	299
56	Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2306-2315.	2.8	296
57	Medical Treatment of Peripheral Arterial Disease. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 547.	7.4	285
58	Clonidine in Patients Undergoing Noncardiac Surgery. <i>New England Journal of Medicine</i> , 2014, 370, 1504-1513.	27.0	285
59	2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2017, 70, 3042-3067.	2.8	285
60	New Antithrombotic Drugs. <i>Chest</i> , 2012, 141, e120S-e151S.	0.8	284
61	Effect of Short-Term vs. Long-Term Blood Storage on Mortality after Transfusion. <i>New England Journal of Medicine</i> , 2016, 375, 1937-1945.	27.0	278
62	Causes of Death and Influencing Factors in Patients With Atrial Fibrillation. <i>Circulation</i> , 2013, 128, 2192-2201.	1.6	268
63	B vitamins in patients with recent transient ischaemic attack or stroke in the VITamins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2010, 9, 855-865.	10.2	264
64	New Anticoagulants. <i>Circulation</i> , 2010, 121, 1523-1532.	1.6	262
65	Risk of Recurrent Venous Thromboembolism in Patients With Common Thrombophilia. <i>Archives of Internal Medicine</i> , 2006, 166, 729.	3.8	259
66	Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin. <i>Circulation</i> , 2013, 128, 2325-2332.	1.6	257
67	Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. <i>European Heart Journal</i> , 2007, 28, 1193-1204.	2.2	253
68	Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1742-1751.	2.8	253
69	Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. <i>European Heart Journal</i> , 2015, 36, 281-288.	2.2	253
70	Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. <i>Lancet</i> , The, 2002, 359, 294-302.	13.7	251
71	The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme. Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. <i>European Heart Journal</i> , 2000, 21, 2033-2041.	2.2	248
72	Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. <i>Lancet</i> , The, 2018, 391, 2325-2334.	13.7	236

#	ARTICLE	IF	CITATIONS
73	Aspirin for the Prevention of Recurrent Venous Thromboembolism. <i>Circulation</i> , 2014, 130, 1062-1071.	1.6	232
74	Association Between High Homocyst(e)ine and Ischemic Stroke due to Large- and Small-Artery Disease but Not Other Etiologic Subtypes of Ischemic Stroke. <i>Stroke</i> , 2000, 31, 1069-1075.	2.0	229
75	Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding. <i>Circulation</i> , 2013, 127, 1404-1412.	1.6	222
76	Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. <i>Blood</i> , 2012, 119, 2172-2174.	1.4	219
77	Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines. <i>Chest</i> , 2012, 141, 53S-70S.	0.8	213
78	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2018, 138, 527-536.	1.6	211
79	Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid. <i>Circulation</i> , 2008, 118, 1705-1712.	1.6	210
80	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1004-1024.	3.4	206
81	Beyond Unfractionated Heparin and Warfarin. <i>Circulation</i> , 2007, 116, 552-560.	1.6	202
82	Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. <i>Thrombosis and Haemostasis</i> , 2015, 113, 625-632.	3.4	201
83	American Association of Orthopedic Surgeons and American College of Chest Physicians Guidelines for Venous Thromboembolism Prevention in Hip and Knee Arthroplasty Differ. <i>Chest</i> , 2009, 135, 513-520.	0.8	200
84	Changes in Renal Function in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2481-2493.	2.8	197
85	The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. <i>Circulation</i> , 2013, 128, 237-243.	1.6	195
86	Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. <i>Lancet</i> , 2009, 374, 565-576.	13.7	188
87	Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. <i>Thrombosis and Haemostasis</i> , 2011, 106, 571-584.	3.4	188
88	2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2020, 76, 594-622.	2.8	187
89	Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS ₂ Score: A Subgroup Analysis of the RE-LY Trial. <i>Annals of Internal Medicine</i> , 2011, 155, 660.	3.9	181
90	Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism. <i>Annual Review of Medicine</i> , 2011, 62, 41-57.	12.2	177

#	ARTICLE	IF	CITATIONS
91	Short-Duration Prophylaxis Against Venous Thromboembolism After Total Hip or Knee Replacement. <i>Archives of Internal Medicine</i> , 2002, 162, 1465.	3.8	170
92	A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The Randomized, phase II study to Evaluate the sAFety and pharmacokinetics of oral dabiGatran etexilate in patients after heart valve replacemeNt (RE-ALIGN). <i>American Heart Journal</i> , 2012, 163, 931-937.e1.	2.7	164
93	Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. <i>Lancet Neurology</i> , The, 2012, 11, 225-231.	10.2	164
94	Approach to Outcome Measurement in the Prevention of Thrombosis in Surgical and Medical Patients. <i>Chest</i> , 2012, 141, e185S-e194S.	0.8	161
95	The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. <i>European Heart Journal</i> , 2013, 34, 170-176.	2.2	160
96	Clinically Significant Pocket Hematoma Increases Long-Term Risk of Device Infection. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1300-1308.	2.8	154
97	Aspirin to Prevent Cardiovascular Disease: The Association of Aspirin Dose and Clopidogrel With Thrombosis and Bleeding. <i>Annals of Internal Medicine</i> , 2009, 150, 379.	3.9	152
98	Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1903-1921.	2.8	150
99	Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. <i>European Heart Journal</i> , 2008, 30, 655-661.	2.2	149
100	Does This Patient Have Pulmonary Embolism?. <i>JAMA - Journal of the American Medical Association</i> , 2003, 290, 2849.	7.4	147
101	Endothelial and Platelet Activation in Acute Ischemic Stroke and Its Etiological Subtypes. <i>Stroke</i> , 2003, 34, 2132-2137.	2.0	147
102	Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. <i>American Heart Journal</i> , 2010, 159, 348-353.e1.	2.7	146
103	Plasma IL-6 and IL-10 Concentrations Predict AKI and Long-Term Mortality in Adults after Cardiac Surgery. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 3123-3132.	6.1	144
104	Monitoring unfractionated heparin with the aPTT: Time for a fresh look. <i>Thrombosis and Haemostasis</i> , 2006, 96, 547-552.	3.4	141
105	Idarucizumab. <i>Circulation</i> , 2015, 132, 2412-2422.	1.6	141
106	The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies. <i>European Heart Journal</i> , 2008, 29, 1057-1071.	2.2	138
107	Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease. <i>American Journal of Medicine</i> , 2011, 124, 621-629.	1.5	134
108	Inherited Thrombophilia in Ischemic Stroke and Its Pathogenic Subtypes. <i>Stroke</i> , 2001, 32, 1793-1799.	2.0	133

#	ARTICLE	IF	CITATIONS
109	Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries. <i>Circulation</i> , 2012, 126, 2309-2316.	1.6	133
110	Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1027-1035.	1.7	133
111	Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. <i>Thrombosis and Haemostasis</i> , 2015, 114, 198-205.	3.4	132
112	Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2). <i>European Heart Journal</i> , 2018, 39, 3973-3979.	2.2	131
113	Unfractionated and Low-Molecular-Weight Heparin as Adjuncts to Thrombolysis in Aspirin-Treated Patients With ST-Elevation Acute Myocardial Infarction. <i>Circulation</i> , 2005, 112, 3855-3867.	1.6	130
114	Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin release assay: a 30-month, 16-patient case series. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 2389-2396.	3.8	127
115	Tranexamic Acid in Patients Undergoing Noncardiac Surgery. <i>New England Journal of Medicine</i> , 2022, 386, 1986-1997.	27.0	125
116	The CHADS2 score for stroke risk stratification in atrial fibrillation – friend or foe?. <i>Thrombosis and Haemostasis</i> , 2010, 104, 45-48.	3.4	124
117	Net Clinical Benefit of Adding Clopidogrel to Aspirin Therapy in Patients With Atrial Fibrillation for Whom Vitamin K Antagonists Are Unsuitable. <i>Annals of Internal Medicine</i> , 2011, 155, 579.	3.9	119
118	Reversal of the antiplatelet effects of aspirin and clopidogrel. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 521-528.	3.8	119
119	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2021, 143, 583-596.	1.6	119
120	Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. <i>European Heart Journal</i> , 2021, 42, 2765-2775.	2.2	119
121	Stroke Outcomes in the COMPASS Trial. <i>Circulation</i> , 2019, 139, 1134-1145.	1.6	118
122	Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. <i>Circulation</i> , 2022, 145, 242-255.	1.6	118
123	Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants. <i>British Journal of Anaesthesia</i> , 2018, 120, 645-656.	3.4	115
124	Triple Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Stents. <i>Circulation</i> , 2010, 121, 2067-2070.	1.6	110
125	Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). <i>European Heart Journal</i> , 2013, 34, 1498-1505.	2.2	109
126	Aspirin resistance: a new independent predictor of vascular events? **Editorials published in the <i>Journal of the American College of Cardiology</i> reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology. <i>Journal of the American College of Cardiology</i> , 2003, 41, 966-968.	2.8	108

#	ARTICLE	IF	CITATIONS
127	Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials. <i>BMC Cardiovascular Disorders</i> , 2015, 15, 96.	1.7	108
128	Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Gastroenterology</i> , 2019, 157, 403-412.e5.	1.3	108
129	Association of atrial fibrillation with mortality and disability after ischemic stroke. <i>Neurology</i> , 2013, 81, 825-832.	1.1	107
130	Homocysteine and stroke. <i>Current Opinion in Neurology</i> , 2001, 14, 95-102.	3.6	106
131	Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 1438-1443.	3.8	106
132	Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease. <i>European Heart Journal</i> , 2015, 36, 1454-1462.	2.2	106
133	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. <i>European Heart Journal</i> , 2017, 38, ehw069.	2.2	106
134	Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2017, 2, 566.	6.1	106
135	Periprocedural Management and Approach to Bleeding in Patients Taking Dabigatran. <i>Circulation</i> , 2012, 126, 2428-2432.	1.6	105
136	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Coronary Stenting. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 522-534.	3.9	103
137	Duration of red cell storage before transfusion and in-hospital mortality. <i>American Heart Journal</i> , 2010, 159, 737-743.e1.	2.7	101
138	Direct oral anticoagulants: evidence and unresolved issues. <i>Lancet</i> , 2020, 396, 1767-1776.	13.7	100
139	Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 33, 88-94.	2.1	99
140	A cohort study examination of established and emerging risk factors for atrial fibrillation: the Busselton Health Study. <i>European Journal of Epidemiology</i> , 2014, 29, 181-190.	5.7	99
141	Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST- and Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Circulation</i> , 2008, 118, 2038-2046.	1.6	98
142	Evolving Treatments for Arterial and Venous Thrombosis. <i>Circulation Research</i> , 2016, 118, 1409-1424.	4.5	96
143	Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease. <i>Circulation</i> , 2020, 141, 1841-1854.	1.6	96
144	Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3271-3280.	2.8	95

#	ARTICLE	IF	CITATIONS
145	Platelet glycoprotein I β Kozak polymorphism is associated with an increased risk of ischemic stroke. <i>Blood</i> , 2001, 98, 36-40.	1.4	94
146	Aspirin resistance: Table 1. <i>BMJ: British Medical Journal</i> , 2004, 328, 477.	2.3	94
147	Homocysteine-Lowering Treatment With Folic Acid, Cobalamin, and Pyridoxine Does Not Reduce Blood Markers of Inflammation, Endothelial Dysfunction, or Hypercoagulability in Patients With Previous Transient Ischemic Attack or Stroke. <i>Stroke</i> , 2005, 36, 144-146.	2.0	94
148	Stroke Risk and Efficacy of Apixaban in Atrial Fibrillation Patients with Moderate Chronic Kidney Disease. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2012, 21, 429-435.	1.6	94
149	Transfusion of fresher vs older red blood cells in hospitalized patients: a systematic review and meta-analysis. <i>Blood</i> , 2016, 127, 400-410.	1.4	94
150	Postoperative Low-Molecular-Weight Heparin Bridging Is Associated with an Increase in Wound Hematoma Following Surgery for Pacemakers and Implantable Defibrillators. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2009, 32, 378-382.	1.2	92
151	A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, Tj ETQq1 1 0.784314 r _g BT /Overlock 10 T	2.2	92
152	Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study. <i>American Heart Journal</i> , 2010, 160, 1178-1184.	2.7	91
153	Adherence to anticoagulant treatment with dabigatran in a real-world setting. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1295-1299.	3.8	91
154	Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. <i>Age and Ageing</i> , 2016, 45, 77-83.	1.6	91
155	Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation. <i>Circulation</i> , 2015, 132, 796-803.	1.6	90
156	Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. <i>European Heart Journal</i> , 2020, 41, 4037-4046.	2.2	90
157	Peripheral arterial disease: prognostic significance and prevention of atherothrombotic complications. <i>Medical Journal of Australia</i> , 2004, 181, 150-154.	1.7	87
158	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2020, 17, 242-257.	13.7	87
159	The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. <i>European Heart Journal</i> , 2012, 33, 2143-2150.	2.2	86
160	Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. <i>Lancet Neurology</i> , The, 2010, 9, 273-284.	10.2	83
161	Bleeding During Treatment With Aspirin Versus Apixaban in Patients With Atrial Fibrillation Unsuitable for Warfarin. <i>Stroke</i> , 2012, 43, 3291-3297.	2.0	83
162	Pacemaker-Detected Atrial Fibrillation in Patients With Pacemakers: Prevalence, Predictors, and Current Use of Oral Anticoagulation. <i>Canadian Journal of Cardiology</i> , 2013, 29, 224-228.	1.7	83

#	ARTICLE	IF	CITATIONS
163	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	3.9	83
164	The COMPASS Trial. <i>Circulation</i> , 2020, 142, 40-48.	1.6	83
165	Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation. <i>Circulation</i> , 2007, 116, 449-455.	1.6	82
166	Recombinant activated factor VII for the treatment of life-threatening haemorrhage. <i>Blood Coagulation and Fibrinolysis</i> , 2003, 14, 713-717.	1.0	81
167	Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. <i>European Heart Journal</i> , 2010, 31, 50-58.	2.2	81
168	Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. <i>Circulation</i> , 2019, 140, 529-537.	1.6	81
169	Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 766-780.	3.3	80
170	Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. <i>PLoS ONE</i> , 2018, 13, e0191592.	2.5	80
171	Laboratory measurement of the direct oral anticoagulants. <i>British Journal of Haematology</i> , 2016, 172, 315-336.	2.5	79
172	Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: A position statement of the Canadian Cardiovascular Society. <i>Canadian Journal of Cardiology</i> , 2009, 25, 683-689.	1.7	78
173	Effects of dabigatran according to age in atrial fibrillation. <i>Heart</i> , 2017, 103, 1015-1023.	2.9	78
174	Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 101-106.	3.8	77
175	Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. <i>Circulation</i> , 2016, 134, 1697-1707.	1.6	76
176	The incidence of venous thromboembolism: a prospective, community-based study in Perth, Western Australia. <i>Medical Journal of Australia</i> , 2008, 189, 144-147.	1.7	75
177	Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. <i>Lancet Neurology</i> , 2012, 11, 1066-1081.	10.2	75
178	Stroke Prevention in Atrial Fibrillation Patients With Chronic Kidney Disease. <i>Canadian Journal of Cardiology</i> , 2013, 29, S71-S78.	1.7	75
179	Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis. <i>Lancet</i> , 2000, 356, 449-454.	13.7	74
180	Major Bleeding, Mortality, and Efficacy of Fondaparinux in Venous Thromboembolism Prevention Trials. <i>Circulation</i> , 2009, 120, 2006-2011.	1.6	74

#	ARTICLE	IF	CITATIONS
181	Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience. <i>American Journal of Medicine</i> , 2016, 129, S33-S40.	1.5	74
182	Anticoagulant-Related Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2787-2793.	6.1	74
183	Protein Z in Ischemic Stroke and its Etiologic Subtypes. <i>Stroke</i> , 2003, 34, 2415-2419.	2.0	73
184	Combined antiplatelet and anticoagulant therapy: clinical benefits and risks. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 255-263.	3.8	73
185	Deep vein thrombosis: update on diagnosis and management. <i>Medical Journal of Australia</i> , 2019, 210, 516-524.	1.7	73
186	B Vitamins and Magnetic Resonance Imaging-â€œDetected Ischemic Brain Lesions in Patients With Recent Transient Ischemic Attack or Stroke. <i>Stroke</i> , 2012, 43, 3266-3270.	2.0	72
187	Anticoagulants in atrial fibrillation patients with chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2012, 8, 569-578.	9.6	72
188	External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. <i>European Heart Journal</i> , 2018, 39, 750-757a.	2.2	72
189	The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics. <i>American Heart Journal</i> , 2019, 218, 46-56.	2.7	72
190	Gastrointestinal bleeding after acute ischemic stroke. <i>Neurology</i> , 2008, 71, 650-655.	1.1	70
191	Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2012, 11, 512-520.	10.2	70
192	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. <i>European Heart Journal</i> , 2016, 38, ehv643.	2.2	69
193	Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion. <i>Journal of the American College of Cardiology</i> , 2019, 73, 121-130.	2.8	69
194	A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1966-1975.	3.8	68
195	Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. <i>Vascular Health and Risk Management</i> , 2015, 11, 343.	2.3	68
196	Effect of B Vitamins and Lowering Homocysteine on Cognitive Impairment in Patients With Previous Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2013, 44, 2232-2239.	2.0	67
197	Accelerated Infusion of Streptokinase for the Treatment of Left-Sided Prosthetic Valve Thrombosis. <i>Circulation</i> , 2009, 120, 1108-1114.	1.6	66
198	Antithrombotic treatment after coronary artery bypass graft surgery: systematic review and network meta-analysis. <i>BMJ: British Medical Journal</i> , 2019, 367, l5476.	2.3	66

#	ARTICLE	IF	CITATIONS
199	Association between phosphodiesterase 4D gene and ischaemic stroke. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 1067-1069.	1.9	65
200	Platelet Function Testing: Quality Assurance. <i>Seminars in Thrombosis and Hemostasis</i> , 2007, 33, 273-282.	2.7	64
201	Homocysteine or Renal Impairment. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 1158-1164.	2.4	63
202	Interleukin-6 and interleukin-10 as acute kidney injury biomarkers in pediatric cardiac surgery. <i>Pediatric Nephrology</i> , 2015, 30, 1519-1527.	1.7	62
203	Translational Success Stories. <i>Circulation Research</i> , 2012, 111, 920-929.	4.5	61
204	The effect of blood storage duration on in-hospital mortality: a randomized controlled pilot feasibility trial. <i>Transfusion</i> , 2012, 52, 1203-1212.	1.6	61
205	Effect of Bile Acid Sequestrants on the Risk of Cardiovascular Events. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 618-627.	5.1	61
206	Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. <i>European Heart Journal</i> , 2002, 23, 1771-1779.	2.2	60
207	Bleeding and management of bleeding. <i>Country Review Ukraine</i> , 2006, 8, G38-G45.	0.8	60
208	New oral anticoagulants in elderly patients. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 215-224.	1.7	60
209	Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 295-301.	2.1	59
210	Balancing the Benefits and Risks of 2 Doses of Dabigatran Compared With Warfarin in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 62, 900-908.	2.8	59
211	Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials. <i>Thrombosis and Haemostasis</i> , 2014, 112, 918-923.	3.4	58
212	Red blood cell processing methods and in-hospital mortality: a transfusion registry cohort study. <i>Lancet Haematology</i> , 2016, 3, e246-e254.	4.6	57
213	Monitoring unfractionated heparin with the aPTT: time for a fresh look. <i>Thrombosis and Haemostasis</i> , 2006, 96, 547-52.	3.4	57
214	Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 255-267.	2.8	56
215	Antiplatelet drugs. <i>Medical Journal of Australia</i> , 2003, 178, 568-574.	1.7	54
216	The effect of long-term homocysteine-lowering on carotid intima-media thickness and flow-mediated vasodilation in stroke patients: a randomized controlled trial and meta-analysis. <i>BMC Cardiovascular Disorders</i> , 2008, 8, 24.	1.7	54

#	ARTICLE	IF	CITATIONS
217	Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes. <i>JAMA Neurology</i> , 2020, 77, 43.	9.0	54
218	Cardiac Biomarkers and Acute Kidney Injury After Cardiac Surgery. <i>Pediatrics</i> , 2015, 135, e945-e956.	2.1	53
219	Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2135-2145.	3.4	53
220	Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study. <i>American Heart Journal</i> , 2016, 178, 145-150.	2.7	52
221	New Anticoagulants for Atrial Fibrillation. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 515-524.	2.7	51
222	The association between blood donor sex and age and transfusion recipient mortality: an exploratory analysis. <i>Transfusion</i> , 2019, 59, 482-491.	1.6	51
223	Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 2649-2655.	3.8	50
224	Protein Z Gene Polymorphisms, Protein Z Concentrations, and Ischemic Stroke. <i>Stroke</i> , 2005, 36, 1123-1127.	2.0	50
225	Aspirin resistance. <i>Thrombosis Research</i> , 2007, 120, 337-346.	1.7	49
226	Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation. <i>Journal of Internal Medicine</i> , 2012, 271, 15-24.	6.0	48
227	New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. <i>Thrombosis and Haemostasis</i> , 2014, 111, 798-807.	3.4	48
228	Antiplatelet Therapy for Secondary Prevention of Noncardioembolic Ischemic Stroke. <i>Stroke</i> , 2008, 39, 1638-1646.	2.0	47
229	Four-Factor Prothrombin Complex Concentrate for Urgent Reversal of Vitamin K Antagonists in Patients With Major Bleeding. <i>Circulation</i> , 2013, 128, 1179-1181.	1.6	47
230	Urgent Need to Measure Effects of Direct Oral Anticoagulants. <i>Circulation</i> , 2016, 134, 186-188.	1.6	47
231	Clinical usefulness of plasma homocysteine in vascular disease. <i>Medical Journal of Australia</i> , 2004, 181, 314-318.	1.7	46
232	New antithrombotic agents—insights from clinical trials. <i>Nature Reviews Cardiology</i> , 2010, 7, 498-509.	13.7	45
233	Normal plasma mixing studies in the laboratory diagnosis of lupus anticoagulant. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 2689-2691.	3.8	44
234	Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD-AF Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e010510.	3.7	44

#	ARTICLE	IF	CITATIONS
235	Prognostic Significance of Thrombocytopenia During Hirudin and Heparin Therapy in Acute Coronary Syndrome Without ST Elevation. <i>Circulation</i> , 2001, 103, 643-650.	1.6	43
236	Bleeding Complications in Acute Coronary Syndromes and Percutaneous Coronary Intervention: Predictors, Prognostic Significance, and Paradigms for Reducing Risk. <i>Clinical Cardiology</i> , 2007, 30, 1124-1134.	1.8	43
237	Mortality outcomes in patients transfused with fresher versus older red blood cells: a meta-analysis. <i>Vox Sanguinis</i> , 2017, 112, 268-278.	1.5	43
238	Low molecular weight heparins and heparinoids. <i>Medical Journal of Australia</i> , 2002, 177, 379-383.	1.7	42
239	Inherited thrombophilia and pregnancy associated venous thromboembolism. <i>BMJ: British Medical Journal</i> , 2007, 334, 1318-1321.	2.3	42
240	Association of cyclooxygenase-2 genetic variant with cardiovascular disease. <i>European Heart Journal</i> , 2014, 35, 2242-2248.	2.2	42
241	Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. <i>American Heart Journal</i> , 2017, 190, 94-103.	2.7	42
242	Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. <i>European Heart Journal</i> , 2011, 32, 2256-2265.	2.2	41
243	A Replacement for Warfarin. <i>Circulation</i> , 2007, 116, 131-133.	1.6	40
244	Assessment of Anticoagulation Intensity and Management of Bleeding With Old and New Oral Anticoagulants. <i>Canadian Journal of Cardiology</i> , 2013, 29, S34-S44.	1.7	40
245	Atrial fibrillation is associated with increased mortality: causation or association?. <i>European Heart Journal</i> , 2013, 34, 1027-1030.	2.2	40
246	Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. <i>Critical Care</i> , 2016, 20, 115.	5.8	40
247	Trends in incidence and prevalence of hospitalization for atrial fibrillation and associated mortality in Western Australia, 1995-2010. <i>International Journal of Cardiology</i> , 2016, 208, 19-25.	1.7	40
248	Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism?. <i>British Journal of Haematology</i> , 2009, 146, 142-149.	2.5	39
249	Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the organization to assess strategies in acute ischemic syndromes (OASIS)-5 trial. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 243-249.	3.8	39
250	Effectiveness and safety of combined antiplatelet and anticoagulant therapy: A critical review of the evidence from randomized controlled trials. <i>Blood Reviews</i> , 2011, 25, 123-129.	5.7	39
251	The effect of homocysteine-lowering with B-vitamins on osteoporotic fractures in patients with cerebrovascular disease: substudy of VITATOPS, a randomised placebo-controlled trial. <i>BMC Geriatrics</i> , 2013, 13, 88.	2.7	39
252	Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2243-2250.	2.8	39

#	ARTICLE	IF	CITATIONS
253	Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). <i>Circulation</i> , 2020, 141, 1141-1151.	1.6	39
254	C-reactive protein in ischemic stroke and its etiologic subtypes. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2003, 12, 74-81.	1.6	38
255	Venous thromboembolism: diagnosis and management of deep venous thrombosis. <i>Medical Journal of Australia</i> , 2005, 182, 476-481.	1.7	38
256	VITATOPS, the VITamins TO Prevent Stroke Trial: Rationale and Design of a Randomised Trial of B-Vitamin Therapy in Patients with Recent Transient Ischaemic Attack or Stroke (NCT00097669) (ISRCTN74743444). <i>International Journal of Stroke</i> , 2007, 2, 144-150.	5.9	38
257	Targeting Cholesterol Crystal-Induced Inflammation for the Secondary Prevention of Cardiovascular Disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 45-52.	2.0	38
258	Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: A nested case control analysis of the ACTIVE W study. <i>Thrombosis Research</i> , 2012, 129, 715-719.	1.7	37
259	Anticoagulation in Patients Aged ≥ 75 years with Atrial Fibrillation: Role of Novel Oral Anticoagulants. <i>Cardiology and Therapy</i> , 2013, 2, 135-149.	2.6	37
260	Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2020, 9, e018984.	3.7	37
261	Methylenetetrahydrofolate Reductase Polymorphisms and Homocysteine-Lowering Effect of Vitamin Therapy in Singaporean Stroke Patients. <i>Stroke</i> , 2006, 37, 456-460.	2.0	36
262	Coagulation Factor IXa as a Target for Treatment and Prophylaxis of Venous Thromboembolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 382-387.	2.4	36
263	Which Risk Factors Are More Associated With Ischemic Stroke Than Intracerebral Hemorrhage in Patients With Atrial Fibrillation?. <i>Stroke</i> , 2012, 43, 2048-2054.	2.0	36
264	Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?. <i>American Heart Journal</i> , 2018, 199, 59-67.	2.7	36
265	Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. <i>Circulation</i> , 2019, 140, 1451-1459.	1.6	36
266	Blood Disorders in Patients Undergoing Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1-11.	2.9	36
267	Collagen platelet receptor polymorphisms integrin $\alpha 2\beta 1$ C807T and GPVI Q317L and risk of ischemic stroke. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 963-970.	3.8	35
268	The evolving role of direct thrombin inhibitors in acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2003, 41, S70-S78.	2.8	35
269	Measurement of soluble P-selectin and soluble CD40 ligand in serum and plasma. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 2067-2069.	3.8	35
270	Association of cardiac biomarkers with acute kidney injury after cardiac surgery: A multicenter cohort study. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 152, 245-251.e4.	0.8	35

#	ARTICLE	IF	CITATIONS
271	Extended-duration versus short-duration pharmacological thromboprophylaxis in acutely ill hospitalized medical patients: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 291-301.	2.1	35
272	Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1468-1483.	2.8	35
273	Skeletonized vs Pedicled Internal Mammary Artery Graft Harvesting in Coronary Artery Bypass Surgery. <i>JAMA Cardiology</i> , 2021, 6, 1042.	6.1	35
274	D-dimer and factor VIIa in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy. <i>Thrombosis and Haemostasis</i> , 2016, 115, 921-930.	3.4	34
275	D-dimer and factor VIIa in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy. <i>Thrombosis and Haemostasis</i> , 2016, 115, 921-930.	3.4	34
276	Dabigatran etexilate and reduction in serum apolipoprotein B. <i>Heart</i> , 2016, 102, 57-62.	2.9	34
277	Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: The BRUISE CONTROL-2 trial. <i>American Heart Journal</i> , 2016, 173, 102-107.	2.7	34
278	Red blood cell storage and in-hospital mortality: a secondary analysis of the INFORM randomised controlled trial. <i>Lancet Haematology</i> , 2017, 4, e544-e552.	4.6	34
279	Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. <i>European Heart Journal</i> , 2019, 40, 3771-3778a.	2.2	34
280	Effect of Long-Term Homocysteine Reduction with B Vitamins on Arterial Wall Inflammation Assessed by Fluorodeoxyglucose Positron Emission Tomography: A Randomised Double-Blind, Placebo-Controlled Trial. <i>Cerebrovascular Diseases</i> , 2009, 27, 259-265.	1.7	33
281	Betrixaban (PRT054021): pharmacology, dose selection and clinical studies. <i>Future Cardiology</i> , 2014, 10, 43-52.	1.2	33
282	Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. <i>Thrombosis and Haemostasis</i> , 2015, 114, 768-777.	3.4	33
283	Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease. <i>JAMA Cardiology</i> , 2021, 6, 21-29.	6.1	33
284	Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: A proposal from the Academic Bleeding Consensus (ABC) Multidisciplinary Working Group. <i>American Heart Journal</i> , 2009, 158, 881-886.e1.	2.7	32
285	A guide to GRADE guidelines for the readers of JTH. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1603-1608.	3.8	32
286	A systematic review of contemporary trials of anticoagulants in orthopaedic thromboprophylaxis: suggestions for a radical reappraisal. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 231-239.	2.1	32
287	Diabetes Mellitus Is Associated With Increased Risk of Ischemic Stroke in Patients With and Without Coronary Artery Disease. <i>Stroke</i> , 2019, 50, 3347-3354.	2.0	32
288	Colchicine for Secondary Prevention of Cardiovascular Disease. <i>Current Atherosclerosis Reports</i> , 2014, 16, 391.	4.8	31

#	ARTICLE	IF	CITATIONS
289	Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial. <i>TH Open</i> , 2017, 01, e139-e145.	1.4	31
290	Variations in incidence of venous thromboembolism in low-, middle-, and high-income countries. <i>Cardiovascular Research</i> , 2021, 117, 576-584.	3.8	31
291	Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2021, 78, 14-23.	2.8	31
292	Dabigatran and risk of myocardial infarction. <i>Nature Reviews Cardiology</i> , 2012, 9, 260-262.	13.7	30
293	Direct thrombin inhibitors in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2012, 9, 402-414.	13.7	30
294	Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1519-1528.	2.8	30
295	Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2141328.	5.9	30
296	Safety Outcomes in Meta-analyses of Phase 2 vs Phase 3 Randomized Trials. <i>JAMA - Journal of the American Medical Association</i> , 2001, 285, 444.	7.4	29
297	Mortality and morbidity following a major bleed in a registry population with acute ST elevation myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 434-440.	2.1	29
298	Updated Meta-Analysis of Aspirin in Primary Prevention of Cardiovascular Disease. <i>American Journal of Medicine</i> , 2016, 129, e35-e36.	1.5	29
299	Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial. <i>Thrombosis Research</i> , 2016, 139, 77-81.	1.7	29
300	Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study establishing diagnostic criteria and prognostic importance. <i>British Journal of Anaesthesia</i> , 2021, 126, 163-171.	3.4	29
301	Who Is (Still) Getting HIT?. <i>Chest</i> , 2007, 131, 1620-1622.	0.8	28
302	Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. <i>American Journal of Hematology</i> , 2009, 84, 579-583.	4.1	28
303	Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial. <i>European Heart Journal</i> , 2014, 35, 1856-1863.	2.2	28
304	Role of phenotypic and genetic testing in managing clopidogrel therapy. <i>Blood</i> , 2014, 124, 689-699.	1.4	28
305	Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. <i>European Heart Journal</i> , 2018, 39, 464-473.	2.2	28
306	Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 296-307.	1.8	28

#	ARTICLE	IF	CITATIONS
307	Biomarker-Based Risk Prediction With the ABC-AF Scores in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation. <i>Circulation</i> , 2021, 143, 1863-1873.	1.6	28
308	Cyclooxygenase-2 Inhibitors. <i>Stroke</i> , 2003, 34, 2736-2740.	2.0	27
309	Failure of Aspirin to Prevent Atherothrombosis. <i>American Journal of Cardiovascular Drugs</i> , 2004, 4, 57-67.	2.2	27
310	Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment. <i>Cardiovascular Research</i> , 2021, 117, 2030-2044.	3.8	27
311	Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2021, 78, 859-866.	2.8	27
312	Lack of consistency in the relationship between asymptomatic DVT detected by venography and symptomatic VTE in thromboprophylaxis trials. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1049-1057.	3.4	26
313	Efficacy of hirudin in reducing cardiovascular events in patients with acute coronary syndrome undergoing early percutaneous coronary intervention. <i>European Heart Journal</i> , 2002, 23, 117-123.	2.2	25
314	Venous thromboembolism: diagnosis and management of pulmonary embolism. <i>Medical Journal of Australia</i> , 2005, 182, 569-574.	1.7	25
315	The aspirin controversy in primary prevention. <i>Current Opinion in Cardiology</i> , 2012, 27, 499-507.	1.8	25
316	Effect of <i>PON1</i> Q192R Genetic Polymorphism on Clopidogrel Efficacy and Cardiovascular Events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events Trial and the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events. <i>Circulation: Cardiovascular Genetics</i> , 2012, 5, 250-256.	5.1	25
317	Exploratory studies on the age of transfused blood and in-hospital mortality in patients with cardiovascular diagnoses. <i>Transfusion</i> , 2015, 55, 364-372.	1.6	25
318	Perioperative heart-type fatty acid binding protein is associated with acute kidney injury after cardiac surgery. <i>Kidney International</i> , 2015, 88, 576-583.	5.2	25
319	Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 23-34.	2.1	25
320	Bleeding with direct oral anticoagulants vs warfarin: clinical experience. <i>American Journal of Emergency Medicine</i> , 2016, 34, 3-8.	1.6	25
321	Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: A retrospective population-based cohort study. <i>European Journal of Internal Medicine</i> , 2016, 33, 55-59.	2.2	25
322	Design of a Randomized Placebo-Controlled Trial to Assess Dabigatran and Omeprazole in Patients with Myocardial Injury after Noncardiac Surgery (MANAGE). <i>Canadian Journal of Cardiology</i> , 2018, 34, 295-302.	1.7	25
323	Effect of Direct Oral Anticoagulants, Warfarin, and Antiplatelet Agents on Risk of Device Pocket Hematoma. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e007545.	4.8	25
324	Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. <i>European Heart Journal</i> , 2020, 41, 2848-2859.	2.2	25

#	ARTICLE	IF	CITATIONS
325	Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy. <i>Stroke</i> , 2021, 52, 2096-2105.	2.0	25
326	Dabigatran etexilate for prevention of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2009, 101, 2-4.	3.4	25
327	Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention. <i>European Heart Journal</i> , 2005, 26, 2396-2403.	2.2	24
328	Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 127-132.	2.1	24
329	Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1228-1235.	3.4	24
330	Randomized controlled trial of a new portable calf compression device (Venowave) for prevention of venous thrombosis in high-risk neurosurgical patients. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 229-235.	3.8	24
331	Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1760-1768.	2.8	24
332	Reduction in Mortality following Elective Major Hip and Knee Surgery: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2019, 119, 668-674.	3.4	24
333	Homocysteine and stroke. <i>Lancet</i> , 2005, 365, 194-196.	13.7	24
334	Modification of Outcomes With Aspirin or Apixaban in Relation to CHADS ₂ and CHA ₂ DS ₂ -VASc Scores in Patients With Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2013, 6, 31-38.	4.8	23
335	Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target. <i>Kidney International</i> , 2021, 100, 1199-1207.	5.2	23
336	Perioperative Aspirin for Prevention of Venous Thromboembolism. <i>Anesthesiology</i> , 2016, 125, 1121-1129.	2.5	22
337	Apixaban for Stroke Prevention in Atrial Fibrillation: Why are Event Rates Higher in Clinical Practice than in Randomized Trials? A Systematic Review. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1323-1329.	3.4	22
338	Lower versus Standard INR Targets in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Thrombosis and Haemostasis</i> , 2020, 120, 484-494.	3.4	22
339	Venous thromboembolism in travellers. <i>Blood Coagulation and Fibrinolysis</i> , 2003, 14, 671-675.	1.0	21
340	High prevalence of abnormal preoperative coagulation tests in patients with adolescent idiopathic scoliosis. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1094-1095.	3.8	21
341	Adding aspirin to clopidogrel after TIA and ischemic stroke. <i>Neurology</i> , 2005, 64, 1117-1121.	1.1	21
342	The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: insights from the AVERROES trial. <i>European Heart Journal</i> , 2013, 34, 2752-2759.	2.2	21

#	ARTICLE	IF	CITATIONS
343	Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. <i>Pharmacogenomics</i> , 2016, 17, 1425-1439.	1.3	21
344	The Ross procedure versus prosthetic and homograft aortic valve replacement: a systematic review and meta-analysis. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 247-255.	1.4	21
345	Treatment With B Vitamins and Incidence of Cancer in Patients With Previous Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2012, 43, 1572-1577.	2.0	20
346	Targeting the Unstable Plaque in Acute Coronary Syndromes. <i>Clinical Therapeutics</i> , 2013, 35, 1099-1107.	2.5	20
347	Recent Advances in Antidotes for Direct Oral Anticoagulants: Their Arrival Is Imminent. <i>Canadian Journal of Cardiology</i> , 2014, 30, 381-384.	1.7	20
348	Fatty acid binding protein 3 is associated with peripheral arterial disease. <i>JVS Vascular Science</i> , 2020, 1, 168-175.	1.1	20
349	Thromboprophylaxis practice patterns in two Western Australian teaching hospitals. <i>Haematologica</i> , 2004, 89, 586-93.	3.5	20
350	Homocysteine Levels in Patients with Stroke. <i>CNS Drugs</i> , 2001, 15, 437-443.	5.9	19
351	Routine home treatment of deep vein thrombosis. <i>BMJ: British Medical Journal</i> , 2001, 322, 1192-1193.	2.3	19
352	Antithrombotic treatment for peripheral arterial disease. <i>Heart</i> , 2007, 93, 303-308.	2.9	19
353	CYP2C19 Genetic Testing Should Not Be Done in All Patients Treated With Clopidogrel Who Are Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 514-521.	3.9	19
354	Antiplatelet Therapy and Cardiac Surgery: Review of Recent Evidence and Clinical Implications. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1042-1047.	1.7	19
355	Antithrombotic Therapy After Acute Ischemic Stroke in Patients With Atrial Fibrillation. <i>Stroke</i> , 2014, 45, 3637-3642.	2.0	19
356	Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention. <i>Circulation</i> , 2016, 133, 2094-2098.	1.6	19
357	Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2016, 18, 973-978.	1.7	19
358	The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population. <i>International Journal of Cardiology</i> , 2019, 278, 7-13.	1.7	19
359	Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban. <i>Thrombosis and Haemostasis</i> , 2022, 122, 998-1005.	3.4	19
360	Associations of homocysteine, C-reactive protein and cardiovascular disease in patients with renal disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2001, 10, 377-383.	2.0	18

#	ARTICLE	IF	CITATIONS
361	Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 493-503.	1.8	18
362	“Real world”™ use of non-vitamin K antagonist oral anticoagulants (NOACs): Lessons from the Dresden NOAC Registry. <i>Thrombosis and Haemostasis</i> , 2015, 113, 1159-1161.	3.4	18
363	Exposure to <sc>ABO</sc> nonidentical blood associated with increased in-hospital mortality in patients with group <sc>A</sc> blood. <i>Transfusion</i> , 2016, 56, 550-557.	1.6	18
364	Pulmonary embolism: update on diagnosis and management. <i>Medical Journal of Australia</i> , 2019, 211, 82-87.	1.7	18
365	Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. <i>Cardiovascular Research</i> , 2022, 118, 2112-2123.	3.8	18
366	Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e181-e189.	1.8	18
367	Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: Results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial. <i>American Heart Journal</i> , 2009, 157, 60-e1-60-e9.	2.7	17
368	Efficacy and safety of early parenteral anticoagulation as a bridge to warfarin after mechanical valve replacement. <i>Thrombosis and Haemostasis</i> , 2014, 112, 1120-1128.	3.4	17
369	Risk of Stent Thrombosis and Major Bleeding with Bivalirudin Compared with Active Control: A Systematic Review and Meta-analysis of Randomized Trials. <i>Thrombosis Research</i> , 2015, 136, 1087-1098.	1.7	17
370	Anticoagulation for Mechanical Heart Valves. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 743-745.	2.4	17
371	Fifty years of research on antithrombotic therapy: Achievements and disappointments. <i>European Journal of Internal Medicine</i> , 2019, 70, 1-7.	2.2	17
372	Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the Atrial Fibrillation and Left Ventricular Hypertrophy Trial. <i>Journal of the American Heart Association</i> , 2019, 8, e010107.	3.7	17
373	Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials. <i>Cardiovascular Research</i> , 2022, 118, 897-903.	3.8	17
374	Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2726-2737.	3.8	17
375	Ximelagatran or Warfarin for Stroke Prevention in Patients With Atrial Fibrillation?. <i>Stroke</i> , 2004, 35, 389-391.	2.0	16
376	The risk of iatrogenic bleeding in acute coronary syndromes and long-term mortality. <i>Current Opinion in Cardiology</i> , 2008, 23, 327-334.	1.8	16
377	The Use of Platelet Function Assays May Help to Determine Appropriate Antiplatelet Treatment Options in a Patient With Recurrent Stroke on Baby Aspirin. <i>Stroke</i> , 2010, 41, 2398-2399.	2.0	16
378	Current Evidence for Genetic Testing in Clopidogrel-Treated Patients Undergoing Coronary Stenting. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 505-513.	3.9	16

#	ARTICLE	IF	CITATIONS
379	The mTORC Pathway in the Antiphospholipid Syndrome. <i>New England Journal of Medicine</i> , 2014, 371, 369-371.	27.0	16
380	Appropriate Apixaban Dosing. <i>JAMA Cardiology</i> , 2016, 1, 635.	6.1	16
381	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. <i>Indian Heart Journal</i> , 2018, 70, 828-835.	0.5	16
382	Editorial Commentâ€”Routine Thrombophilia Testing in Stroke Patients Is Unjustified. <i>Stroke</i> , 2003, 34, 1826-1827.	2.0	15
383	Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions. <i>Medical Journal of Australia</i> , 2004, 181, 524-525.	1.7	15
384	Sustained Homocysteine-Lowering Effect over Time of Folic Acid-Based Multivitamin Therapy in Stroke Patients despite Increasing Folate Status in the Population. <i>Cerebrovascular Diseases</i> , 2005, 19, 110-116.	1.7	15
385	The tissue factor pathway in ischemic stroke. <i>Blood Coagulation and Fibrinolysis</i> , 2006, 17, 527-532.	1.0	15
386	Clopidogrel Resistance. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1935-1937.	2.8	15
387	Efficacy and safety of fondaparinux in patients with ST-segment elevation myocardial infarction across the age spectrum. Results from the Organization for the Assessment of Strategies for Ischemic Syndromes 6Å(OASIS-6) trial. <i>American Heart Journal</i> , 2010, 160, 1049-1055.	2.7	15
388	Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 279-286.	1.5	15
389	Prevention of Thromboembolic Events After Bioprosthetic Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2012, 60, 978-980.	2.8	15
390	Antiplatelet therapy in prevention of cardio- and venous thromboembolic events. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 362-371.	2.1	15
391	Timing the First Postoperative Dose of Anticoagulants. <i>Chest</i> , 2015, 148, 587-595.	0.8	15
392	Rationale and Design of the Informing Fresh versus Old Red Cell Management (INFORM) Trial: An International Pragmatic Randomized Trial. <i>Transfusion Medicine Reviews</i> , 2016, 30, 25-29.	2.0	15
393	Hemodynamic outcomes of the Ross procedure versus other aortic valve replacement: a systematic review and meta-analysis. <i>Journal of Cardiovascular Surgery</i> , 2018, 59, 462-470.	0.6	15
394	How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism. <i>Blood</i> , 2019, 133, 2269-2278.	1.4	15
395	How Did We Get Here?: A Historical Review and Critical Analysis of Anticoagulation Therapy Following Mechanical Valve Replacement. <i>Circulation</i> , 2019, 140, 1933-1942.	1.6	15
396	Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline. <i>Stroke</i> , 2020, 51, 2901-2909.	2.0	15

#	ARTICLE	IF	CITATIONS
397	Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. <i>Cardiovascular Research</i> , 2021, 117, 942-949.	3.8	15
398	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. <i>JAMA Cardiology</i> , 2022, 7, 747.	6.1	15
399	Low-molecular-weight Heparin for the treatment of venous thrombosis in patients with adenocarcinoma. , 1998, 59, 260-261.		14
400	Congestive heart failure complicating non-ST segment elevation acute coronary syndrome: incidence, predictors, and clinical outcomes. <i>Canadian Journal of Physiology and Pharmacology</i> , 2005, 83, 98-103.	1.4	14
401	Clinical factors influencing the sensitivity to warfarin when restarted after surgery. <i>Journal of Internal Medicine</i> , 2008, 263, 412-419.	6.0	14
402	Guidelines for anticoagulant use in acute coronary syndromes. <i>Lancet, The</i> , 2008, 371, 1559-1561.	13.7	14
403	Randomized trial of fondaparinux versus heparin to prevent graft failure after coronary artery bypass grafting: the Fonda CABG study. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 32, 378-385.	2.1	14
404	Sex, Stroke, and Atrial Fibrillation. <i>Archives of Neurology</i> , 2012, 69, 1641.	4.5	14
405	Prognostic importance of preoperative anti-PF4/heparin antibodies in patients undergoing cardiac surgery. <i>Thrombosis and Haemostasis</i> , 2012, 107, 8-14.	3.4	14
406	Novel Oral Anticoagulants for Atrial Fibrillation. <i>Current Atherosclerosis Reports</i> , 2013, 15, 344.	4.8	14
407	Anti- PF_4 /heparin antibodies and venous graft occlusion in postcoronary artery bypass surgery patients randomized to postoperative unfractionated heparin or fondaparinux thromboprophylaxis. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 253-260.	3.8	14
408	Quantification of Cell-Free DNA in Red Blood Cell Units in Different Whole Blood Processing Methods. <i>Journal of Blood Transfusion</i> , 2016, 2016, 1-5.	3.3	14
409	Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events. <i>Thrombosis Research</i> , 2016, 140, 81-88.	1.7	14
410	International Normalized Ratio Targets for Left-Sided Mechanical Valve Replacement. <i>Thrombosis and Haemostasis</i> , 2018, 118, 906-913.	3.4	14
411	Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time—A RE-LY trial analysis. <i>American Heart Journal</i> , 2018, 198, 169-177.	2.7	14
412	Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1097-1106.	3.4	14
413	New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty. <i>BMJ: British Medical Journal</i> , 2011, 342, c7270-c7270.	2.3	13
414	Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 429-436.	2.1	13

#	ARTICLE	IF	CITATIONS
415	Subtle differences in commercial heparins can have serious consequences for cardiopulmonary bypass patients: A randomized controlled trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 144, 944-950.e3.	0.8	13
416	Aspirin response variability after major orthopedic surgery. <i>Thrombosis Research</i> , 2012, 130, 216-220.	1.7	13
417	Efficacy and Safety of Warfarin VS. Antiplatelet Therapy in Patients with Systolic Heart Failure and Sinus Rhythm: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>International Journal of Stroke</i> , 2014, 9, 199-206.	5.9	13
418	Measurement of Dabigatran Drug Levels to Manage Patients Taking Interacting Drugs: A Case Report. <i>American Journal of Medicine</i> , 2016, 129, e247-e248.	1.5	13
419	Trends in Perioperative Venous Thromboembolism Associated with Major Noncardiac Surgery. <i>TH Open</i> , 2017, 01, e82-e91.	1.4	13
420	Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 908-918.	2.7	13
421	Recurrent palmar-plantar erythrodysesthesia following high-dose cytarabine treatment for acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , 2002, 69, 315-317.	2.2	12
422	Bone marrow biopsy in thrombocytopenic or anticoagulated patients. <i>British Journal of Haematology</i> , 2005, 129, 562-563.	2.5	12
423	Selective factor Xa inhibition for thromboprophylaxis. <i>Lancet, The</i> , 2008, 372, 6-8.	13.7	12
424	Effect of fondaparinux 2.5 mg once daily on mortality: a meta-analysis of phase III randomized trials of venous thromboembolism prevention. <i>Country Review Ukraine</i> , 2008, 10, C8-C13.	0.8	12
425	Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 965-972.	1.5	12
426	The hazards of interrupting anticoagulation therapy in atrial fibrillation. <i>European Heart Journal</i> , 2012, 33, 1864-1866.	2.2	12
427	Heparin bridging in peri-procedural management of new oral anticoagulant: a bridge too far?. <i>European Heart Journal</i> , 2014, 35, 1831-1833.	2.2	12
428	Novel Oral Anticoagulants: A Focused Review for Stroke Physicians. <i>International Journal of Stroke</i> , 2014, 9, 71-78.	5.9	12
429	Advances in Thrombosis and Hemostasis. <i>Circulation Research</i> , 2016, 118, 1337-1339.	4.5	12
430	External applicability of the COMPASS trial: the Western Denmark Heart Registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 192-199.	3.0	12
431	Aortic plaque burden predicts vascular events in patients with cardiovascular disease: The EAST-NOGA study. <i>Journal of Cardiology</i> , 2022, 79, 144-152.	1.9	12
432	Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI). <i>Blood</i> , 2018, 132, LBA-1-LBA-1.	1.4	12

#	ARTICLE	IF	CITATIONS
433	Approach to the new oral anticoagulants in family practice: part 1: comparing the options. Canadian Family Physician, 2014, 60, 989-95.	0.4	12
434	Conduit selection and early graft failure in coronary artery bypass surgery: A post hoc analysis of the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) coronary artery bypass grafting study. Journal of Thoracic and Cardiovascular Surgery, 2023, 165, 1080-1089.e1.	0.8	12
435	SUBOPTIMAL PREVENTIVE PRACTICES IN PATIENTS WITH CAROTID AND PERIPHERAL VASCULAR OCCLUSIVE DISEASE IN A TERTIARY REFERRAL SETTING. ANZ Journal of Surgery, 2003, 73, 932-937.	0.7	11
436	Management of peripheral arterial disease in the elderly: focus on cilostazol. Clinical Interventions in Aging, 2008, Volume 3, 17-23.	2.9	11
437	Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients. Thrombosis Research, 2010, 125, e128-e131.	1.7	11
438	Use of Clopidogrel Post-Coronary Artery Bypass Surgery in Canadian Patients With Acute Coronary Syndromes. Canadian Journal of Cardiology, 2011, 27, 711-715.	1.7	11
439	Chills and limb pain following administration of low-molecular-weight heparin for treatment of acute venous thromboembolism. American Journal of Hematology, 2011, 86, 603-606.	4.1	11
440	Warfarin in Heart Failure. New England Journal of Medicine, 2012, 366, 1936-1938.	27.0	11
441	The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop. Transfusion, 2012, 52, 1363-1378.	1.6	11
442	Procoagulants for management of bleeding with the new oral anticoagulants. Thrombosis and Haemostasis, 2013, 110, 01.	3.4	11
443	Modification of Outcomes With Aspirin or Apixaban in Relation to Female and Male Sex in Patients With Atrial Fibrillation. Stroke, 2014, 45, 2127-2130.	2.0	11
444	Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes. Thrombosis and Haemostasis, 2015, 114, 933-944.	3.4	11
445	Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation. Thrombosis and Haemostasis, 2016, 115, 257-270.	3.4	11
446	Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. International Journal of Stroke, 2019, 14, 270-281.	5.9	11
447	Illustrated State-of-the-Art Capsules of the ISTH 2019 Congress in Melbourne, Australia. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 431-497.	2.3	11
448	Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation. Circulation, 2019, 139, 2846-2856.	1.6	11
449	Quality of early evidence on the pathogenesis, diagnosis, prognosis and treatment of COVID-19. BMJ Evidence-Based Medicine, 2021, 26, 302-306.	3.5	11
450	Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. Journal of the American College of Cardiology, 2021, 77, 511-525.	2.8	11

#	ARTICLE	IF	CITATIONS
451	Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale. <i>American Heart Journal</i> , 2021, 233, 48-58.	2.7	11
452	Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 648-659.	3.0	11
453	Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). <i>American Journal of Cardiology</i> , 2021, 149, 27-35.	1.6	11
454	Hypercoagulability and thrombosis in COVID-19: a modifiable cause for mortality?. <i>European Heart Journal</i> , 2021, 42, 3143-3145.	2.2	11
455	Systematic Review of Observational Studies Assessing Bleeding Risk in Patients with Atrial Fibrillation Not Using Anticoagulants. <i>PLoS ONE</i> , 2014, 9, e88131.	2.5	11
456	Randomised comparative effectiveness trial of Pulmonary Embolism Prevention after hiP and kneE Replacement (PEPPER): the PEPPER trial protocol. <i>BMJ Open</i> , 2022, 12, e060000.	1.9	11
457	Red cell N5-methyltetrahydrofolate concentrations and C677T methylenetetrahydrofolate reductase genotype in patients with stroke. <i>Journal of Clinical Pathology</i> , 2004, 57, 54-57.	2.0	10
458	Latest medical treatment strategies for venous thromboembolism. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1221-1233.	1.8	10
459	Overexpression of the Multidrug Resistance Protein-4 Transporter in Patients Undergoing Coronary Artery Bypass Graft Surgery. <i>Journal of the American College of Cardiology</i> , 2011, 58, 762-764.	2.8	10
460	Importance of Family History as a Risk Factor for Venous Thromboembolism. <i>Circulation</i> , 2011, 124, 996-997.	1.6	10
461	Anticoagulants in Patients with Atrial Fibrillation and End-Stage Renal Disease. <i>Postgraduate Medicine</i> , 2012, 124, 17-25.	2.0	10
462	Venous thromboembolism prophylaxis: do trial results enable clinicians and patients to evaluate whether the benefits justify the risk? Proceedings of an Ad Hoc Working Group Meeting. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 778-782.	3.8	10
463	Mandatory contrast-enhanced venography to detect deep-vein thrombosis (DVT) in studies of DVT prophylaxis: upsides and downsides. <i>Thrombosis and Haemostasis</i> , 2014, 111, 10-13.	3.4	10
464	Cluster randomized controlled trial of a simple warfarin maintenance dosing algorithm versus usual care among primary care practices. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 435-442.	2.1	10
465	Comparison of Frequency of Ischemic Stroke in Patients With Versus Without Coronary Heart Disease and Without Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2019, 123, 153-158.	1.6	10
466	Selection Bias, Orthopaedic Style. <i>Journal of Bone and Joint Surgery - Series A</i> , 2020, 102, 631-633.	3.0	10
467	Anticoagulation for Stroke Prevention in Patients With Atrial Fibrillation and End-Stage Renal Disease—First, Do No Harm. <i>JAMA Network Open</i> , 2020, 3, e202237.	5.9	10
468	Homocyst(e)ine and Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2000, 132, 676.	3.9	10

#	ARTICLE	IF	CITATIONS
469	Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions. <i>Canadian Family Physician</i> , 2014, 60, 997-1001.	0.4	10
470	Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery. <i>Trials</i> , 2022, 23, 101.	1.6	10
471	Thromboprophylaxis practice patterns in hip fracture surgery patients: experience in Perth, Western Australia. <i>ANZ Journal of Surgery</i> , 2003, 73, 826-829.	0.7	9
472	Folic Acid-Based Multivitamin Therapy to Prevent Stroke. <i>Stroke</i> , 2004, 35, 1995-1998.	2.0	9
473	Point-of-care testing for assessment of adequacy of oral antiplatelet therapy in patients with cardiovascular disease. <i>Future Cardiology</i> , 2010, 6, 289-299.	1.2	9
474	DABIGATRAN VERSUS WARFARIN IN ATRIAL FIBRILLATION PATIENTS WITH LOW, MODERATE AND HIGH CHADS2 SCORE: A RE-LY SUBGROUP ANALYSIS. <i>Journal of the American College of Cardiology</i> , 2010, 55, A1.E2.	2.8	9
475	Randomized controlled trials of new oral anticoagulants for stroke prevention in atrial fibrillation. <i>Current Opinion in Cardiology</i> , 2012, 27, 331-339.	1.8	9
476	Dabigatran efficacy-safety assessment for stroke prevention in patients with atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 966-968.	3.8	9
477	Processed residual pump blood in cardiac surgery: the Processed Residual Blood in Cardiac surgery trial. <i>Transfusion</i> , 2013, 53, 1487-1492.	1.6	9
478	Dabigatran monitoring made simple?. <i>Thrombosis and Haemostasis</i> , 2013, 110, 393-395.	3.4	9
479	Dabigatran in clinical practice: Contemporary overview of the evidence. <i>International Journal of Cardiology</i> , 2016, 220, 417-428.	1.7	9
480	Nadroparin for the prevention of venous thromboembolism in nonsurgical patients: a systematic review and meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 90-98.	2.1	9
481	Assessing renal function in patients receiving DOACs: Cockcroft-Gault versus estimated glomerular filtration rate. <i>Thrombosis Research</i> , 2017, 157, 165-166.	1.7	9
482	Long-Term Efficacy of Colchicine in Patients With Chronic Coronary Disease: Insights From LoDoCo2. <i>Circulation</i> , 2022, 145, 626-628.	1.6	9
483	Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin. <i>New England Journal of Medicine</i> , 2002, 346, 1589-1590.	27.0	8
484	The beginning of the end of warfarin?. <i>Medical Journal of Australia</i> , 2004, 180, 549-551.	1.7	8
485	Renal Function, Peak Anti-Xa Levels and Enoxaparin Dosing. <i>Journal of Pharmacy Practice and Research</i> , 2004, 34, 14-17.	0.8	8
486	What do the results of the PRoFESS trial teach us?. <i>Lancet Neurology</i> , The, 2008, 7, 860-862.	10.2	8

#	ARTICLE	IF	CITATIONS
487	New pharmacotherapy for stroke prevention in atrial fibrillation: Update 2010. <i>Advances in Therapy</i> , 2009, 26, 1058-1071.	2.9	8
488	Otamixaban in acute coronary syndromes. <i>Lancet, The</i> , 2009, 374, 762-764.	13.7	8
489	Preventing Cardioembolic Stroke in Atrial Fibrillation with Dabigatran. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 17-23.	4.2	8
490	Anticoagulant therapy in acute brain ischaemia. <i>Lancet Neurology, The</i> , 2013, 12, 526-527.	10.2	8
491	Immature Platelet Count. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2130-2132.	2.8	8
492	Platelet Transfusion for Ticagrelor Reversal. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	8
493	Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: a systematic review and network meta-analysis of randomized controlled trials. <i>Journal of Cardiovascular Surgery</i> , 2017, 59, 128-139.	0.6	8
494	In Vitro Reversal of the Anti-Aggregant Effect of Ticagrelor Using Untreated Platelets. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1895-1901.	3.4	8
495	Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. <i>Thrombosis and Haemostasis</i> , 2019, 119, 576-585.	3.4	8
496	Antiplatelet Therapy versus Anticoagulation after Surgical Bioprosthetic Aortic Valve Replacement: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2019, 119, 328-339.	3.4	8
497	Preoperative prediction of Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study. <i>British Journal of Anaesthesia</i> , 2021, 126, 172-180.	3.4	8
498	Direct Oral Anticoagulant Dosing in Extremes of Body Weight: Time to Revisit the Guidelines?. <i>Thrombosis and Haemostasis</i> , 2021, 121, 118-120.	3.4	8
499	Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES. <i>Thrombosis and Haemostasis</i> , 2021, 121, 518-528.	3.4	8
500	Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease. <i>Cardiovascular Research</i> , 2022, 118, 295-304.	3.8	8
501	Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 462-473.	3.0	8
502	Oral anticoagulation versus antiplatelet therapy for secondary stroke prevention in patients with embolic stroke of undetermined source: A systematic review and meta-analysis. <i>European Stroke Journal</i> , 2022, 7, 92-98.	5.5	8
503	Dual antithrombotic treatment in chronic coronary syndrome: European Society of Cardiology criteria vs. CHADS-P2A2RC score. <i>European Heart Journal</i> , 2022, 43, 996-1004.	2.2	8
504	von Willebrand Disease Associated with Superficial Temporal Artery Pseudoaneurysm. <i>European Journal of Vascular and Endovascular Surgery</i> , 2005, 30, 285-287.	1.5	7

#	ARTICLE	IF	CITATIONS
505	Pexelizumab Does Not "Complement" Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 91.	7.4	7
506	Ethnicity Does Not Affect the Homocysteine-Lowering Effect of B-Vitamin Therapy in Singaporean Stroke Patients. <i>Stroke</i> , 2009, 40, 2209-2211.	2.0	7
507	Validity of Composite Outcomes in Meta-Analyses of Stroke Prevention Trials: The Case of Aspirin. <i>Cerebrovascular Diseases</i> , 2011, 32, 22-27.	1.7	7
508	The serological profile of early-onset and persisting post-cardiac surgery thrombocytopenia complicated by "true" heparin-induced thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2012, 107, 998-1000.	3.4	7
509	Prevention of thromboembolism in the patient with acute coronary syndrome and atrial fibrillation. <i>Current Opinion in Cardiology</i> , 2014, 29, 1-9.	1.8	7
510	A Risk Assessment Tool Incorporating New Biomarkers for Cardiovascular Events in Acute Coronary Syndromes: The Organization to Assess Strategies in Ischemic Syndromes (OASIS) Risk Score. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1332-1339.	1.7	7
511	Clinical implications of reversal agents for direct oral anticoagulants. <i>Future Cardiology</i> , 2017, 13, 153-159.	1.2	7
512	Aortic valve replacement in younger patients. <i>European Heart Journal</i> , 2017, 38, 3378-3381.	2.2	7
513	Reversal of the antiplatelet effect of ticagrelor by simulated platelet transfusion. <i>Transfusion</i> , 2019, 59, 1850-1856.	1.6	7
514	Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease. <i>American Heart Journal</i> , 2019, 218, 100-109.	2.7	7
515	2020 Asian Pacific Society of Cardiology Consensus Recommendations on Antithrombotic Management for High-risk Chronic Coronary Syndrome. <i>European Cardiology Review</i> , 2021, 16, e26.	2.2	7
516	Post-operative pain following cardiac implantable electronic device implantation: insights from the BRUISE CONTROL trials. <i>Europace</i> , 2021, 23, 748-756.	1.7	7
517	Management and Outcomes of Major Bleeding On Dabigatran or Warfarin. <i>Blood</i> , 2012, 120, 19-19.	1.4	7
518	How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland?. <i>Kardiologia Polska</i> , 2019, 77, 661-669.	0.6	7
519	New oral anticoagulants: not quite there yet. <i>Polish Archives of Internal Medicine</i> , 2009, 119, 53-59.	0.4	7
520	Inflammation as a Mechanism and Therapeutic Target in Peripheral Artery Disease. <i>Canadian Journal of Cardiology</i> , 2022, 38, 588-600.	1.7	7
521	Carbamazepine, phenytoin, and oral anticoagulants: Drug-drug interaction and clinical events in a retrospective cohort. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12650.	2.3	7
522	Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial. <i>European Heart Journal</i> , 2022, 43, 3542-3552.	2.2	7

#	ARTICLE	IF	CITATIONS
523	Management of Patients with Acute Coronary Syndromes. <i>Drugs</i> , 2002, 62, 1839-1852.	10.9	6
524	Ximelagatran or warfarin in atrial fibrillation?. <i>Lancet, The</i> , 2004, 363, 734.	13.7	6
525	Low-Molecular-Weight Heparin as an Adjunct to Thrombolysis in ST Elevation Myocardial Infarction. <i>Archives of Internal Medicine</i> , 2009, 169, 1163.	3.8	6
526	Another oral thrombin inhibitor for stroke prevention in atrial fibrillation?. <i>Thrombosis and Haemostasis</i> , 2010, 103, 481-483.	3.4	6
527	Should adult patients be routinely tested for heritable thrombophilia after an episode of venous thromboembolism?. <i>Medical Journal of Australia</i> , 2011, 195, 139-142.	1.7	6
528	The King is Dead (Warfarin): Direct Thrombin and Factor Xa Inhibitors: The Next Diadochian War?. <i>International Journal of Stroke</i> , 2012, 7, 139-141.	5.9	6
529	Stroke prevention in older adults with atrial fibrillation. <i>Cmaj</i> , 2013, 185, 1479-1480.	2.0	6
530	Direct-Acting Oral Anticoagulants. <i>JAMA Neurology</i> , 2013, 70, 1483-4.	9.0	6
531	Switching Patients From Blinded Study Drug to Warfarin at the End of the ENGAGE AF-TIMI 48 Trial. <i>Journal of the American College of Cardiology</i> , 2014, 64, 585-587.	2.8	6
532	Intensity and Quality of Warfarin Anticoagulation in Chinese Patients. <i>Stroke</i> , 2015, 46, 5-6.	2.0	6
533	Ciraparantag for enoxaparin reversal: Adding to the evidence. <i>Thrombosis Research</i> , 2016, 146, 106-107.	1.7	6
534	Antithrombotic Treatments for Stroke Prevention in Elderly Patients With Nonvalvular Atrial Fibrillation: Drugs and Doses. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1108-1116.	1.7	6
535	Bleeding impacting mortality after noncardiac surgery: a protocol to establish diagnostic criteria, estimate prognostic importance, and develop and validate a prediction guide in an international prospective cohort study. <i>CMAJ Open</i> , 2017, 5, E594-E603.	2.4	6
536	Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS. <i>Future Cardiology</i> , 2018, 14, 443-453.	1.2	6
537	Patients with Peripheral Artery Disease in the COMPASS Trial. <i>European Journal of Vascular and Endovascular Surgery</i> , 2018, 56, 772-773.	1.5	6
538	Plasma Apixaban Levels in Patients Treated Off Label With the Lower Dose. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2906-2907.	2.8	6
539	Plasma Levels of Protein Z in Ischemic Stroke: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2020, 120, 815-822.	3.4	6
540	Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. <i>Heart</i> , 2021, 107, 1130-1137.	2.9	6

#	ARTICLE	IF	CITATIONS
541	Exposure To ABO Compatible But Non-Group Identical Blood and In-Hospital Mortality. <i>Blood</i> , 2013, 122, 3651-3651.	1.4	6
542	Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 786-795.	3.0	6
543	Detection of protein s deficiency: a new functional assay compared to an antigenic technique. <i>Pathology</i> , 2000, 32, 94-97.	0.6	5
544	Adjunctive Use of Direct Thrombin Inhibitors in Patients Receiving Fibrinolytic Therapy for Acute Myocardial Infarction. <i>American Journal of Cardiovascular Drugs</i> , 2004, 4, 107-115.	2.2	5
545	Anticoagulation for venous thromboembolism. <i>BMJ: British Medical Journal</i> , 2007, 334, 645-645.	2.3	5
546	Will prasugrel supersede clopidogrel for acute coronary syndromes?. <i>Medical Journal of Australia</i> , 2008, 188, 381-382.	1.7	5
547	Anticoagulation for ST-Segment Elevation Myocardial Infarction. <i>Circulation</i> , 2009, 119, 1186-1188.	1.6	5
548	Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 241-249.	1.5	5
549	A National Survey of Canadian Practice Patterns of Warfarin After Anterior Wall Myocardial Infarction in the Current Era of Dual Antiplatelet Therapy. <i>American Journal of Cardiology</i> , 2010, 105, 1844.	1.6	5
550	Apixaban in Acute Coronary Syndromes. <i>Cardiovascular Therapeutics</i> , 2011, 29, 285-290.	2.5	5
551	More on Acutely Injured Patients Receiving Dabigatran. <i>New England Journal of Medicine</i> , 2012, 366, 863-864.	27.0	5
552	Antithrombotic therapy for stroke prevention in atrial fibrillation and mechanical heart valves. <i>American Journal of Hematology</i> , 2012, 87, S100-7.	4.1	5
553	Aspirin for Preventing Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2013, 368, 772-773.	27.0	5
554	Reply. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2885-2886.	2.8	5
555	Short-Term versus Long-Term Blood Storage. <i>New England Journal of Medicine</i> , 2017, 376, 1091-1094.	27.0	5
556	Direct Oral Anticoagulants and Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 27-28.	2.8	5
557	Quantifying immature platelets as markers of increased platelet production after coronary artery bypass grafting surgery. <i>European Journal of Haematology</i> , 2018, 101, 362-367.	2.2	5
558	Monitoring Emerging Data From the COMPASS Trial of an Antithrombotic Agent. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2769-2772.	2.8	5

#	ARTICLE	IF	CITATIONS
559	Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence. <i>Future Cardiology</i> , 2019, 15, 395-404.	1.2	5
560	Evaluation of the Age, Biomarkers, and Clinical Historyâ€“Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials. <i>JAMA Network Open</i> , 2020, 3, e2015943.	5.9	5
561	Using aspirin to prevent cognitive decline. <i>BMJ: British Medical Journal</i> , 2008, 337, a958-a958.	2.3	5
562	Intensified antiplatelet therapy in patients after percutaneous coronary intervention with high onâ€“treatment platelet reactivity: the OPTImal Management of Antithrombotic Agents (OPTIMA)â€“ Trial. <i>British Journal of Haematology</i> , 2021, , .	2.5	5
563	Venous thrombosis and hyperhomocysteinaemia. <i>Medical Journal of Australia</i> , 1998, 169, 313-315.	1.7	4
564	Intracranial haemorrhage with bolus thrombolytic agents. <i>Lancet, The</i> , 2000, 356, 1850.	13.7	4
565	Antiplatelet Agents in Acute Coronary Syndromes. <i>Seminars in Vascular Medicine</i> , 2003, 03, 403-414.	2.1	4
566	Evaluation of the phospholipid-rich dilute Russell's viper venom assay to monitor oral anticoagulation in patients with lupus anticoagulant. <i>Blood Coagulation and Fibrinolysis</i> , 2004, 15, 353-357.	1.0	4
567	Treatment of Restenosis with a Paclitaxel-Coated Balloon Catheter. <i>New England Journal of Medicine</i> , 2007, 356, 1071-1073.	27.0	4
568	The Pursuit of Clinically Relevant Measures of Platelet Function After Antiplatelet Drug Therapyâ€“Zâ€“ Editorials published in the <i>Journal of the American College of Cardiology</i> reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1978-1980.	2.8	4
569	Duration of anticoagulant therapy for venous thromboembolism. <i>Medical Journal of Australia</i> , 2009, 190, 659-660.	1.7	4
570	How can we reduce disagreement among guidelines for venous thromboembolism prevention?. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 675-677.	3.8	4
571	Is there really misuse and abuse of dabigatran?. <i>Medical Journal of Australia</i> , 2013, 198, 358-359.	1.7	4
572	Rapid reversal of haematoma expansion associated with vitamin K antagonists. <i>Lancet Neurology, The</i> , 2016, 15, 535-537.	10.2	4
573	Which Patients With Atrial Fibrillation and Chronic Kidney Disease Should Receive Anticoagulationâ€“And With Which Anticoagulant?. <i>Canadian Journal of Cardiology</i> , 2017, 33, 211-213.	1.7	4
574	Reduced-Intensity Anticoagulation for Mechanical Aortic Valve Prostheses. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2727-2730.	2.8	4
575	Risk stratification of cardiovascular complications using CHA2DS2-VASc and CHADS2 scores in chronic atherosclerotic cardiovascular disease. <i>International Journal of Cardiology</i> , 2021, 337, 9-15.	1.7	4
576	Ross for Valve replacement In AduLts (REVIVAL) pilot trial: rationale and design of a randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e046198.	1.9	4

#	ARTICLE	IF	CITATIONS
577	Direct oral anticoagulant dose selection: Challenging cases. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2680-2686.	3.8	4
578	Can a Single Measurement of Apixaban Levels Identify Patients at Risk of Overexposure? A Prospective Cohort Study. <i>TH Open</i> , 2022, 06, e10-e17.	1.4	4
579	The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges. <i>CJC Open</i> , 2022, 4, 568-576.	1.5	4
580	Exacerbation of coagulopathy with concurrent bone marrow necrosis, hepatic and renal dysfunction secondary to all-trans retinoic acid therapy for acute promyelocytic leukemia. , 1997, 15, 13-17.		3
581	Aspirin for the primary prevention of cardiovascular events. <i>Medical Journal of Australia</i> , 2002, 177, 343-344.	1.7	3
582	Response to Letter Regarding Article, "Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid: Determinants and Effect on Cardiovascular Risk" <i>Circulation</i> , 2009, 119, .	1.6	3
583	Rivaroxaban versus enoxaparin after total knee arthroplasty. <i>Lancet</i> , The, 2009, 374, 681.	13.7	3
584	Deep Vein Thrombosis Prophylaxis: Response. <i>Chest</i> , 2009, 136, 1700-1701.	0.8	3
585	Does dabigatran improve stroke-prevention in atrial fibrillation? Reply to a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1438-1439.	3.8	3
586	New oral anticoagulants for stroke prevention in atrial fibrillation. <i>Clinical Investigation</i> , 2011, 1, 3-7.	0.0	3
587	Old blood bad? Either the biggest issue in transfusion medicine or a nonevent. <i>Transfusion</i> , 2012, 52, 1165-1167.	1.6	3
588	Response to Letter Regarding Article, "Causes of Death and Influencing Factors in Patients With Atrial Fibrillation: A Competing-Risk Analysis From the Randomized Evaluation of Long-Term Anticoagulant Therapy Study" <i>Circulation</i> , 2014, 130, e85.	1.6	3
589	Stroke prevention in atrial fibrillation: Commentary regarding the AAN's evidence-based guideline update. <i>Neurology: Clinical Practice</i> , 2014, 4, 96-98.	1.6	3
590	Shorter or longer anticoagulation to prevent recurrent venous thromboembolism: systematic review and meta-analysis. <i>BMJ Open</i> , 2014, 4, e005674-e005674.	1.9	3
591	Proton-pump inhibitors for the prevention of upper gastrointestinal bleeding in adults receiving antithrombotic therapy. <i>The Cochrane Library</i> , 2019, , .	2.8	3
592	Stroke prevention in AF: Of Asians and non-Asians. <i>European Heart Journal</i> , 2019, 40, 1528-1530.	2.2	3
593	Tranexamic acid and rosuvastatin in patients at risk of cardiovascular events after noncardiac surgery: a pilot of the POISE-3 randomized controlled trial. <i>Pilot and Feasibility Studies</i> , 2020, 6, 104.	1.2	3
594	The Indirect Consequences of the Response to the COVID-19 Pandemic. <i>Journal of the American College of Cardiology</i> , 2021, 77, 186-188.	2.8	3

#	ARTICLE	IF	CITATIONS
595	Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI). <i>Vascular Health and Risk Management</i> , 2006, 2, 379-387.	2.3	3
596	Apixaban Versus Dalteparin for Thromboprophylaxis in Patients with Acute Spinal Cord Injury: A Pilot Study. <i>Blood</i> , 2019, 134, 2434-2434.	1.4	3
597	The reemergence of aspirin for the prevention of venous thromboembolism. <i>Clinical Advances in Hematology and Oncology</i> , 2012, 10, 120-1.	0.3	3
598	Preventing Thromboembolic Complications in Older Orthopaedic Surgery Patients. <i>Drugs and Aging</i> , 1999, 15, 297-306.	2.7	2
599	Direct thrombin inhibitors in acute coronary syndromes. <i>Lancet, The</i> , 2002, 360, 492.	13.7	2
600	Is there a role for laboratory testing to identify patients at risk of aspirin treatment failure?. <i>Blood Coagulation and Fibrinolysis</i> , 2004, 15, 129-130.	1.0	2
601	Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions. <i>Medical Journal of Australia</i> , 2005, 182, 199-199.	1.7	2
602	Treatment of Antiphospholipid Antibody Syndrome—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 42.	7.4	2
603	Role of protein Z in stroke. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2007, 9, 191-197.	0.9	2
604	Role of triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. <i>Medical Journal of Australia</i> , 2010, 192, 487-488.	1.7	2
605	Reply to Letters Regarding Article, “Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial”. <i>Circulation</i> , 2012, 125, .	1.6	2
606	Idrabiotaparinux treatment for venous thromboembolism. <i>Lancet, The</i> , 2012, 379, 96-98.	13.7	2
607	Reducing the risk of recurrent stroke in patients with AF. <i>Lancet Neurology, The</i> , 2012, 11, 479-481.	10.2	2
608	Anticoagulation management in patients with mechanical heart valves having pacemaker or defibrillator insertion. <i>Thrombosis Research</i> , 2013, 131, 300-303.	1.7	2
609	Response to Letters Regarding Article, “Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”. <i>Circulation</i> , 2013, 127, e506.	1.6	2
610	Is There a Role for Betrixaban to Prevent Stroke in Medically Ill Patients?. <i>Circulation</i> , 2017, 135, 656-658.	1.6	2
611	Impact of cost on use of non-vitamin K antagonists in atrial fibrillation patients in Ontario, Canada. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 310-315.	2.1	2
612	Plasma Rivaroxaban Level to Identify Patients at Risk of Drug Overexposure: Is a Single Measurement of Drug Level Reliable?. <i>TH Open</i> , 2021, 05, e84-e88.	1.4	2

#	ARTICLE	IF	CITATIONS
613	What is the role of growth-differentiation factor-15 in biomarker-based prediction of mortality in patients with atrial fibrillation?. <i>European Journal of Internal Medicine</i> , 2021, 88, 23-24.	2.2	2
614	Pharmacodynamic effects of indobufen compared with aspirin in patients with coronary atherosclerosis. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1815-1823.	1.9	2
615	Treatment of intermittent claudication. <i>BMJ: British Medical Journal</i> , 2009, 338, b46-b46.	2.3	2
616	Bleeding in Patients with Atrial Fibrillation Treated with Non Vitamin K Antagonist Oral Anticoagulants: A Population-Based Study. <i>Blood</i> , 2014, 124, 343-343.	1.4	2
617	Bleeding in Patients with Atrial Fibrillation Treated with Different Doses of Direct Oral Anticoagulants and Vitamin K Antagonists: A Population-Based Study. <i>Blood</i> , 2016, 128, 2617-2617.	1.4	2
618	Dabigatran: ready for prime time?. <i>Polish Archives of Internal Medicine</i> , 2010, 120, 137-142.	0.4	2
619	Advances in anticoagulation: patients with bioprosthetic heart valves. <i>Cardiovascular Research</i> , 2022, 118, e26-e28.	3.8	2
620	Nonbleeding complications of unfractionated and low-molecular weight heparins. <i>Clinical Advances in Hematology and Oncology</i> , 2007, 5, 871-3.	0.3	2
621	Management of unstable angina and myocardial infarction. <i>Lancet, The</i> , 2000, 356, 1193-1194.	13.7	1
622	Management of unstable coronary-artery disease. <i>Lancet, The</i> , 2000, 355, 572.	13.7	1
623	The tip of the iceberg?. <i>Lancet, The</i> , 2002, 359, 2194.	13.7	1
624	Long-term management of venous thromboembolism: is there a role for low-intensity warfarin therapy?. <i>Medical Journal of Australia</i> , 2003, 179, 68-69.	1.7	1
625	Bone marrow biopsy morbidity and mortality: 2002 data.. <i>International Journal of Laboratory Hematology</i> , 2005, 27, 209-210.	0.2	1
626	More on: enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1639-1640.	3.8	1
627	Guidelines for anticoagulant use in acute coronary syndromes – Authors' reply. <i>Lancet, The</i> , 2008, 372, 533-534.	13.7	1
628	Double-dose clopidogrel in patients undergoing PCI for ACS – Authors' reply. <i>Lancet, The</i> , 2011, 377, 298.	13.7	1
629	Response to Letter Regarding Article, "Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized) Trial". <i>Circulation</i> , 2014, 129, 1081-1082.	10.784314	1
630	Dabigatran-related coagulopathy: when can we assume the effect has worn off?. <i>American Journal of Emergency Medicine</i> , 2014, 32, 1433-1434.	1.6	1

#	ARTICLE	IF	CITATIONS
631	Reply. Journal of the American College of Cardiology, 2015, 66, 2682.	2.8	1
632	Evaluating coagulation tests in patients with atrial fibrillation using direct oral anticoagulants. Expert Review of Cardiovascular Therapy, 2015, 13, 1213-1223.	1.5	1
633	HERDOO2 identified women at low risk for recurrence after 5 to 12 mo of anticoagulation for a first unprovoked VTE. Annals of Internal Medicine, 2017, 167, JC33.	3.9	1
634	Reply. Gastroenterology, 2020, 158, 1175-1176.	1.3	1
635	Cardiac Tamponade During Uninterrupted Oral Anticoagulant Therapy for Catheter Ablation for Atrial Fibrillation. JACC: Clinical Electrophysiology, 2020, 6, 796-798.	3.2	1
636	Oral factor Xa inhibitors and risk of subdural hematoma. Neurology, 2020, 95, e480-e487.	1.1	1
637	Mortality benefit in the COMPASS trial: is it related to superior statistical power or better efficacy and safety?. Future Cardiology, 2021, 17, 175-182.	1.2	1
638	Letter to the editor: Colchicine and risk of non-cardiovascular death in patients with coronary artery disease: a pooled analysis underlying possible safety concerns. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e71-e71.	3.0	1
639	Life and limb protection with dual anti-thrombotic pathway inhibition: COMPASS ushers in a new day in atherothrombotic risk reduction. Med, 2021, 2, 233-242.	4.4	1
640	Elevated plasma levels of NT-proBNP in ambulatory patients with peripheral arterial disease. PLoS ONE, 2021, 16, e0253792.	2.5	1
641	Clinical factors associated with peripheral artery disease in patients with documented coronary artery disease: A post hoc analysis of the COMPASS trial. Atherosclerosis, 2021, 331, 38-44.	0.8	1
642	Strategies for the prevention and treatment of bleeding in patients treated with dabigatran: an update. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 1091-1102.	3.3	1
643	Systematic Review to Identify Validated Manual Warfarin Maintenance Dosing Tools.. Blood, 2010, 116, 3800-3800.	1.4	1
644	Utilization of Universal Group O Blood By Non Group O Recipients. Blood, 2014, 124, 5103-5103.	1.4	1
645	Low Molecular Weight Heparin and Bleeding in Patients with Severe Renal Failure: A Meta-Analysis.. Blood, 2005, 106, 907-907.	1.4	1
646	Unmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban. Cardiology Research, 2015, 6, 267-277.	1.1	1
647	Management of bleeding with oral anticoagulants in patients with atrial fibrillation. Hamostaseologie, 2015, 35, 351-357.	1.9	1
648	Dual and triple antithrombotic therapies: current patterns of practice and controversies. Kardiologia Polska, 2018, 76, 937-944.	0.6	1

#	ARTICLE	IF	CITATIONS
649	Effects of Andexanet Alfa on Thrombin Generation in Bleeding Associated with Factor Xa Inhibitors. <i>Blood</i> , 2019, 134, 711-711.	1.4	1
650	Prolonged Blood Storage and Risk of Posttransfusion Acute Kidney Injury. <i>Anesthesiology</i> , 2022, 136, 138-147.	2.5	1
651	Homocysteine-lowering therapy improved outcomes after percutaneous coronary intervention. <i>ACP Journal Club</i> , 2003, 138, 33.	0.1	1
652	Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis. <i>Circulation</i> , 2022, 145, 1875-1877.	1.6	1
653	Prothrombin 20210A and familial thrombophilia. <i>Blood Coagulation and Fibrinolysis</i> , 1999, 10, 523-527.	1.0	0
654	Homocysteine and cardiovascular risk: is it time to treat?. <i>Evidence-based Cardiovascular Medicine</i> , 1999, 3, 59-60.	0.0	0
655	Broadsheet number 53: activated protein c resistance: diagnosis and clinical management. <i>Pathology</i> , 1999, 31, 365-371.	0.6	0
656	Enoxaparin was superior to heparin in preventing serious cardiac ischemic events in patients with unstable angina/non-Q-wave MI. <i>Evidence-based Cardiovascular Medicine</i> , 2000, 4, 45.	0.0	0
657	In reply: Low-molecular-weight heparins and heparinoids. <i>Medical Journal of Australia</i> , 2003, 178, 414-415.	1.7	0
658	Venous thromboembolism: diagnosis and management of pulmonary embolism. <i>Medical Journal of Australia</i> , 2005, 183, 220-221.	1.7	0
659	ESPRIT trial. <i>Lancet, The</i> , 2006, 368, 447.	13.7	0
660	Homocysteine-Should We Screen and Treat in Preventive Cardiology Programs?. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2006, 26, 281-287.	0.5	0
661	Medical Management of Peripheral Arterial Disease—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 41.	7.4	0
662	The Outpatient Bleeding Risk Index predicted major bleeding in patients taking warfarin. <i>Evidence-Based Medicine</i> , 2006, 11, 120-120.	0.6	0
663	Pexelizumab and the APEX AMI Trial—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1877.	7.4	0
664	Guidelines for the management of acute coronary syndromes 2006. <i>Medical Journal of Australia</i> , 2007, 186, 101-102.	1.7	0
665	Simplifying the diagnosis of pulmonary embolism. <i>Medical Journal of Australia</i> , 2007, 187, 325-326.	1.7	0
666	Response to Letter Regarding Article, “Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation”. <i>Circulation</i> , 2008, 117, .	1.6	0

#	ARTICLE	IF	CITATIONS
667	Cyclooxygenase Inhibitors. , 0, , 31-46.		0
668	New Anticoagulants for Atrial Fibrillation. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 711-711.	2.7	0
669	Anticoagulants for patients with prosthetic heart valves – Authors' reply. <i>Lancet</i> , The, 2009, 374, 1499-1500.	13.7	0
670	Percutaneous closure of the left atrial appendage was noninferior to warfarin in atrial fibrillation. <i>Annals of Internal Medicine</i> , 2009, 151, JC5.	3.9	0
671	Explaining the RE-LY Trial. <i>Canadian Journal of Hospital Pharmacy</i> , 2010, 63, 334-6.	0.1	0
672	New Anticoagulants for Atrial Fibrillation: The Beginning of a A New Era in Stroke Prevention. <i>Canadian Journal of Neurological Sciences</i> , 2011, 38, 777-782.	0.5	0
673	Antithrombotic Therapy After Coronary Artery Stenting in Patients With Atrial Fibrillation. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 454-455.	3.9	0
674	Letter by Van de Werf et al Regarding Article, “Using Dabigatran in Patients With Stroke: A Practical Guide for Clinicians” • <i>Stroke</i> , 2012, 43, e46-7; author reply e49.	2.0	0
675	REVERSAL OF THE ANTI-PLATELET EFFECTS OF ASPIRIN AND CLOPIDOGREL. <i>Heart</i> , 2012, 98, E272.2-E272.	2.9	0
676	Dabigatran for patients with a mechanical valve. <i>Heart Lung and Circulation</i> , 2012, 21, 121.	0.4	0
677	Should Warfarin Be Restarted After Warfarin-Associated Intracranial Hemorrhage?. <i>Canadian Journal of Cardiology</i> , 2012, 28, 6-8.	1.7	0
678	A response to - There's madness in their methods. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 785-786.	3.8	0
679	Venous Thrombosis. , 2013, , 619-626.		0
680	Response to Letter Regarding Article, “Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin” • <i>Circulation</i> , 2014, 130, e95.	1.6	0
681	Review: New oral anticoagulants increase GI bleeding in venous thrombosis and ACS. <i>Annals of Internal Medicine</i> , 2014, 160, JC4.	3.9	0
682	Mechanical left atrial appendage closure was noninferior and superior to warfarin in atrial fibrillation. <i>Annals of Internal Medicine</i> , 2015, 162, JC4.	3.9	0
683	Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin. <i>Evidence-Based Medicine</i> , 2015, 20, 117-117.	0.6	0
684	How good is aspirin for patients with acute brain ischaemia?. <i>Nature Reviews Neurology</i> , 2016, 12, 434-435.	10.1	0

#	ARTICLE	IF	CITATIONS
685	Response by Weitz and Eikelboom to Letter Regarding Article, "Urgent Need to Measure Effects of Direct Oral Anticoagulants". <i>Circulation</i> , 2016, 134, e498.	1.6	0
686	Letter to the Editor. <i>Journal of Intensive Care Medicine</i> , 2016, 31, 70-71.	2.8	0
687	Enhanced TRAP-induced platelet aggregation with dabigatran " Clinical perspective. <i>Thrombosis Research</i> , 2016, 138, 61-62.	1.7	0
688	Resuming warfarin after intracranial hemorrhage in patients with AF was linked to reduced mortality. <i>Annals of Internal Medicine</i> , 2017, 166, JC70.	3.9	0
689	In Reply. <i>Anesthesiology</i> , 2017, 127, 401-402.	2.5	0
690	Rivaroxaban with or without aspirin for prevention of cardiovascular disease. <i>Coronary Artery Disease</i> , 2018, 29, 361-365.	0.7	0
691	The value of novel oral anticoagulants in rural Australia. <i>Medical Journal of Australia</i> , 2018, 208, 15-16.	1.7	0
692	Response to: Unacceptable conflicts of interest (Br J Anaesth 2018; 121: 1183). <i>British Journal of Anaesthesia</i> , 2018, 121, 1183-1184.	3.4	0
693	Reply. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2360.	2.8	0
694	Review: After PCI with DESs, long- and standard-term DAPT increase some adverse outcomes vs short-term DAPT. <i>Annals of Internal Medicine</i> , 2019, 171, JC54.	3.9	0
695	NOACs only for those who cannot tolerate a VKA: where is the evidence?. <i>Acta Cardiologica</i> , 2019, 74, 17-20.	0.9	0
696	Reply. <i>Gastroenterology</i> , 2020, 158, 285-286.	1.3	0
697	Mortality benefits of thromboprophylaxis. <i>Lancet Haematology</i> , 2020, 7, e783.	4.6	0
698	Is aspirin safer than a direct oral anticoagulant for patients with atrial fibrillation at high risk of bleeding?. <i>European Journal of Internal Medicine</i> , 2020, 79, 25-26.	2.2	0
699	Rivaroxaban for the prevention of major adverse cardiovascular events in patients with coronary or peripheral artery disease. <i>Future Cardiology</i> , 2020, 16, 597-611.	1.2	0
700	Prothrombin Complex Concentrates for Intracranial Hemorrhage on Factor Xa Inhibitors. <i>Circulation</i> , 2020, 141, 1690-1692.	1.6	0
701	Optimal Prescription of the Lower Dose of Apixaban. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1156-1158.	2.8	0
702	Oral Anticoagulant Treatment in Patients with Atrial Fibrillation and Cancer. <i>Thrombosis and Haemostasis</i> , 2020, 120, 194-196.	3.4	0

#	ARTICLE	IF	CITATIONS
703	Direct Oral Anticoagulant Reversal for Management of Bleeding and Emergent Surgery. , 2021, , 71-91.		0
704	Reply. Journal of the American College of Cardiology, 2021, 77, 2757.	2.8	0
705	Efficacy and safety of low intensity vitamin K antagonists in Western and East-Asian patients with left-sided mechanical heart valves. Journal of Thrombosis and Thrombolysis, 2021, , 1.	2.1	0
706	Design of trials to evaluate antiplatelet agents. , 2002, , 1003-1012.		0
707	Low-Molecular-Weight Heparin for Pulmonary Embolism. Annals of Internal Medicine, 2004, 141, 407.	3.9	0
708	Oral antiplatelet therapy. , 2011, , 311-319.		0
709	Effect of a Perioperative Hypotension-Avoidance Strategy Versus a Hypertension-Avoidance Strategy on the Risk of Acute Kidney Injury: A Clinical Research Protocol for a Substudy of the POISE-3 Randomized Clinical Trial. Canadian Journal of Kidney Health and Disease, 2022, 9, 205435812110692.	1.1	0
710	Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962110739.	1.7	0
711	Homocysteine-lowering therapy improved outcomes after percutaneous coronary intervention. ACP Journal Club, 2003, 138, 33.	0.1	0
712	Review: MTHFR TT genotype increases risk for coronary heart disease. ACP Journal Club, 2003, 138, 79.	0.1	0
713	High- and moderate-intensity warfarin regimens did not differ for preventing thrombosis in antiphospholipid antibody syndrome. ACP Journal Club, 2004, 140, 38.	0.1	0
714	Aspirin resistance: does it exist and is it an important clinical problem?. Clinical Advances in Hematology and Oncology, 2006, 4, 268-70.	0.3	0
715	Thrombolytic Therapy for Deep Vein Thrombosis and Pulmonary Embolism. , 0, , 88-98.		0
716	Review: MTHFR TT genotype increases risk for coronary heart disease. ACP Journal Club, 2003, 138, 79.	0.1	0
717	High- and moderate-intensity warfarin regimens did not differ for preventing thrombosis in the antiphospholipid antibody syndrome. ACP Journal Club, 2004, 140, 38.	0.1	0